Endocrinology, Vol 120, 381-388, Copyright © 1987 by Endocrine Society

ARTICLES

Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number

BJ Gertz, LN Contreras, DJ McComb, K Kovacs, JB Tyrrell and MF Dallman

The effect of chronic administration of CRF on rat pituitary morphology was studied. Experimental animals received CRF (10 micrograms/day) over a period of 52 days by means of sc osmotic pumps changed at 10- to 14- day intervals. The average 0800 h plasma corticosterone levels in the treated animals were significantly greater than control values [7.52 +/- 0.99 (+/- SE) vs. 1.14 +/- 0.5 micrograms/dl; P less than 0.001]. The CRF-treated animals also had a significantly greater adrenal weight (16.44 +/- 1.38 vs. 12.24 +/- 0.85 mg; P less than 0.05) and lower thymus weight (164 +/- 12 vs. 248 +/- 27 mg; P less than 0.005). There was a marked increase in the number of ACTH-producing cells in the anterior pituitaries of the rats that received CRF (13.3 +/- 0.8% vs. 4.5 +/- 0.3% ACTH-producing cells; P less than 0.001), as determined by immunocytochemical methods. Corticotrophs of rats treated with CRF manifested a significant increase in nuclear area (24.0 +/- 0.7 vs. 21.4 +/- 0.4 micron 2; P less than 0.001) and an increased diameter of forming and storage granules (191.1 +/- 1.1 vs. 158.6 +/- 3.5 nm and 196.1 +/- 1.2 vs. 170.1 +/- 3.7 nm, respectively; P less than 0.001). There was no demonstrable increase in ACTH cell area. These data indicate that long term administration of CRF is capable of increasing the number of pituitary corticotrophs. It also supports the view that the corticotroph hyperplasia occurring after adrenalectomy, in unusual cases of ectopic CRF production, and in rare instances of Cushing's disease is a proliferative response to CRF.

This article has been cited by other articles:

				J. L. Smart, V. Tolle, V. Otero-Corchon, and M. J. Low Central Dysregulation of the Hypothalamic-Pituitary-Adrenal Axis in Neuron-Specific Proopiomelanocortin-Deficient Mice Endocrinology, February 1, 2007; 148(2): 647 - 659. [Abstract] [Full Text] [PDF]

				K. Pals, M. Boussemaere, E. Swinnen, H. Vankelecom, and C. Denef A Pituitary Cell Type Coexpressing Messenger Ribonucleic Acid of Proopiomelanocortin and the Glycoprotein Hormone {alpha}-Subunit in Neonatal Rat and Chicken: Rapid Decline with Age and Reappearance in Vitro under Regulatory Pressure of Corticotropin-Releasing Hormone in the Rat Endocrinology, October 1, 2006; 147(10): 4738 - 4752. [Abstract] [Full Text] [PDF]

				S. A. Stanley, K. G. Murphy, G. A. Bewick, W. M. Kong, J. Opacka-Juffry, J. V. Gardiner, M. Ghatei, C. J. Small, and S. R. Bloom Regulation of rat pituitary cocaine- and amphetamine-regulated transcript (CART) by CRH and glucocorticoids Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E583 - E590. [Abstract] [Full Text] [PDF]

				R. Ramesh, W.J. Kuenzel, and J.A. Proudman Increased Proliferative Activity and Programmed Cellular Death in the Turkey Hen Pituitary Gland Following Interruption of Incubation Behavior Biol Reprod, February 1, 2001; 64(2): 611 - 618. [Abstract] [Full Text]

				B. Xu, T. Sano, S. Yamada, C. C. Li, and M. Hirokawa Expression of Corticotropin-Releasing Hormone Messenger Ribonucleic Acid in Human Pituitary Corticotroph Adenomas Associated with Proliferative Potential J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1220 - 1225. [Abstract] [Full Text]

				S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]

				H. Yano, C. Readhead, M. Nakashima, S.-G. Ren, and S. Melmed Pituitary-Directed Leukemia Inhibitory Factor Transgene Causes Cushing's Syndrome: Neuro-Immune-Endocrine Modulation of Pituitary Development Mol. Endocrinol., November 1, 1998; 12(11): 1708 - 1720. [Abstract] [Full Text]

				D. N. Orth Cushing's Syndrome N. Engl. J. Med., March 23, 1995; 332(12): 791 - 803. [Full Text] [PDF]